STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.

Trial Details

NCT ID
NCT07213570
Phase
PHASE2
Sponsor
National Cancer Institute, Naples
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • standard second line treatment, at discretion of the investigator
  • Regorafenib (BAY73-4506)
Locations (sample)
  • Naples, Italy, Italy|40.85216,14.26811

Key Eligibility Criteria

  • Written informed consent to study procedures and to correlative studies.
  • Either sex aged ≥ 18.
  • Histologically proven of colorectal adenocarcinoma.
  • Diagnosis of metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →